CTOs on the Move

Inflammatix

www.inflammatix.com

 
Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Joao Fonseca
 Chief Technology Officer Profile

Funding

Inflammatix raised $32M on 01/10/2020
Inflammatix raised $102M on 03/16/2021

Similar Companies

Aptus Genomics

Aptus Genomics is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Renaissance RX

Renaissance RX is on the forefront of the new era of personalized medicine. The laboratory provides Pharmacogenetic Testing and Advanced Toxicology to give doctors unique insight into each individual patient with the most accurate and actionable information. The results are healthier patients and more successful medical practices. To compliment lab services and help ensure drug adherence, Renaissance RX offers access to its online medication portal and the Virtual PharmD Intelligence Engine.

Columbus Children's Research Institute

Columbus Children's Research Institute is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.